News

Phase III trials of DSC 127 (Derma Sciences) start for Diabetic Foot Ulcers

Derma Sciences, Inc. has announced enrollment of patients has commenced in the first of two Phase III clinical trials with the Company’s investigational topical drug candidate DSC 127.

DSC 127 is an analog of a naturally occurring peptide, Angiotensin. It has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization.

The two pivotal trials ...

Tavaborole (Anacor Pharma) success in Phase III for Onychomycosis

Anacor Pharmaceuticals has announced positive preliminary results from the first of two Phase III trials of tavaborole, its topical anti-fungal for Onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Tavaborole achieved a high degree of statistical significance on all primary and secondary endpoints.

In this first Phase ...

Two Phase III studies of efinaconazole (Valeant Pharma) show positive results in patients with Onychomycosis

Positive results have been published from two pivotal, Phase III multicenter, randomized, double-blind, vehicle-controlled studies of efinaconazole, from Valeant Pharma, that were conducted in 1,655 subjects with Onychomycosis. The study's primary endpoint was the complete cure rate at Week 52, meaning the target nail showed no clinical involvement and no evidence of fungus present by both KOH testing and a ...

BioChaperone(Adocia) success in Phase II trial for Diabetic Foot Ulcers

Phase II results of BioChaperone demonstrated non-inferiority in a comparison with Johnson & Johnson/Healthpoint Biotherapeutic's Regranex gel 0.01% (becaplermin).Analysis of negative side effects, collected through the intent-to-treat population of 192 patients, did not identify any serious side effect related to the treatment. These safety results indicate that BioChaperone PDGF-BB is well tolerated and safe at the three doses tested for ...